glycine has been researched along with Hematologic Diseases in 7 studies
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 9.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, S | 1 |
| Moreau, P | 1 |
| Hari, P | 1 |
| Mateos, MV | 1 |
| Ludwig, H | 1 |
| Shustik, C | 1 |
| Masszi, T | 1 |
| Spencer, A | 1 |
| Hájek, R | 1 |
| Romeril, K | 1 |
| Avivi, I | 1 |
| Liberati, AM | 1 |
| Minnema, MC | 1 |
| Einsele, H | 1 |
| Lonial, S | 1 |
| Berg, D | 1 |
| Lin, J | 1 |
| Gupta, N | 1 |
| Esseltine, DL | 1 |
| Richardson, PG | 1 |
| Scalzulli, E | 1 |
| Grammatico, S | 1 |
| Vozella, F | 1 |
| Petrucci, MT | 1 |
| BEECKMANS, ML | 1 |
| BERENDSOHN, S | 1 |
| LOWMAN, J | 1 |
| SUNDBERG, D | 1 |
| WATSON, CJ | 1 |
| Takaku, F | 1 |
| Yano, Y | 1 |
| Aoki, Y | 1 |
| Nakao, K | 1 |
| Wada, O | 1 |
| Waxman, S | 1 |
| Corcino, J | 1 |
| Herbert, V | 1 |
| Robinson, SH | 1 |
2 reviews available for glycine and Hematologic Diseases
| Article | Year |
|---|---|
Proteasome inhibitors for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Dis | 2018 |
Aggravation or initiation of megaloblastosis by amino acids in the diet.
Topics: Amino Acids; Anemia, Pernicious; Cell Nucleus; Diet; DNA; Erythrocytes; Folic Acid; Folic Acid Defic | 1970 |
1 trial available for glycine and Hematologic Diseases
| Article | Year |
|---|---|
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
4 other studies available for glycine and Hematologic Diseases
| Article | Year |
|---|---|
Plasma proteins: studies with C14 labeled glycine in patients with various blood diseases.
Topics: Blood Proteins; Fabaceae; Glycine; Hematologic Diseases; Humans; Vascular Diseases | 1957 |
IDIOPATHIC DYSERYTHROPOIETIC JAUNDICE.
Topics: Anemia; Bile Pigments; Bilirubin; Blood Cell Count; Bone Marrow Examination; Clinical Enzyme Tests; | 1964 |
-Aminolevulinic acid synthetase activity of human bone marrow erythroid cells in various hematological disorders.
Topics: 5-Aminolevulinate Synthetase; Anemia, Hypochromic; Anemia, Sideroblastic; Bone Marrow; Bone Marrow C | 1972 |
The origins of bilirubin.
Topics: Anemia, Hypochromic; Animals; Bilirubin; Carbon Isotopes; Erythropoiesis; Glycine; Hematologic Disea | 1968 |